A growing focus on real world insight
Real world evidence has become an increasingly important feature of the UK life sciences landscape. As organisations seek better ways to understand how treatments perform outside controlled research environments, attention has turned to the practical value of data generated through routine clinical care. This shift reflects a wider ambition to improve the relevance, responsiveness and effectiveness of research and development. Real world evidence offers insights that complement traditional clinical trials and can help shape decision making across healthcare, regulation and industry.
Understanding patient experience in everyday settings
Real world evidence is particularly significant because it captures patient experience in everyday settings. While clinical trials provide essential information about safety and efficacy, they cannot account fully for the complexities of real clinical practice. Variations in patient characteristics, adherence, comorbidities and service delivery can all influence outcomes. Real world data allows these factors to be considered more directly. For organisations seeking to design therapies and technologies that respond to actual patient needs, these insights are invaluable.
Using NHS data to strengthen research and evaluation
The development of stronger digital foundations within the NHS has created new opportunities to use real world data more effectively. Improved data systems can support secure and consistent access to information drawn from across the health service. When data can be linked and analysed with confidence, researchers can investigate patterns of care, evaluate service performance and explore how treatments work for diverse patient groups. This capability strengthens the evidence available to clinicians and policymakers while also informing the development of new products.
Industry interest in real world evidence
Industry partners have also shown increased interest in incorporating real world evidence into development processes. Access to detailed, longitudinal data can help organisations refine study designs, identify meaningful endpoints and understand unmet need more clearly. These insights can support both early stage research and later phase evaluation, making development more efficient and more closely aligned with patient experience. Real world evidence does not replace clinical trials but enriches them by providing additional context that can shape strategic decisions.
Challenges in data quality and interoperability
However, the use of real world data brings its own challenges. Ensuring data quality is essential, as inconsistent or incomplete information can limit the value of analysis. Interoperability across systems is another important consideration. When systems do not communicate effectively, opportunities to link and analyse data at scale can be reduced. Addressing these issues requires sustained investment in digital infrastructure and close collaboration across the NHS, research partners and industry.
Maintaining public trust and transparent governance
Public trust is equally important. Real world evidence relies on data that reflects patient interactions with the health system, and maintaining confidence in how this data is used, stored and shared is crucial. Transparent governance, strong safeguards and clear communication help ensure that data is handled responsibly. When patients understand the benefits of real world evidence and feel confident in the protections surrounding their data, engagement and support tend to increase.
Informing service improvement and clinical decision making
Real world evidence also has implications for healthcare delivery. Insights drawn from everyday clinical practice can help identify opportunities for service improvement and guide resource allocation. When clinicians have access to relevant and timely evidence, they can make decisions that better reflect the needs of their patient population. This strengthens the overall quality and consistency of care while supporting a more responsive health system.
Looking ahead to a data-informed future
As the UK continues to advance its life sciences ambitions, real world evidence will play an increasingly central role. The ability to generate and apply insights from routine care enhances research, strengthens regulatory decision making and supports innovation across the sector. Achieving this requires strong digital foundations, a skilled workforce, clear governance and continued collaboration across the ecosystem.
Real world evidence represents both an opportunity and a responsibility. It offers a richer and more representative understanding of health outcomes, while also demanding careful attention to data quality, transparency and public trust. With sustained focus and coordinated action, the UK can make real world evidence a defining strength of its life sciences environment, ensuring that research and innovation remain closely aligned with the realities of patient care.
